Compass Pathways
CMPS
Performance
About Compass Pathways
Compass Pathways is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health care. The company studies investigational psilocybin therapies for treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa, aiming to advance clinical science and therapeutic options. Headquartered in London, the organization engages in global research collaborations and publishes results from its COMP360 program and related trials. Compass emphasizes patient-centric approaches and responsible clinical development in neuroscience-driven mental health treatment.
Recent News
Psychedelic Practitioner Issue 4 Highlights Integration as Key to Psychedelic Healing
AtaiBeckley Shares Jump 21% After Trump Orders Faster Psychedelic Drug Reviews
Can an LSD Candidate Do for Anxiety What Spravato Did for Depression?
FDA Grants Three Priority Vouchers to Psychedelics
Single 25 Mg Psilocybin Dose Triggers Lasting Brain Entropy and Boosts Well‑Being
StockWatch: Trump Order Lifts Psychedelic Drug Shares
New Antidepressants: Tackling Treatment Resistant Depression
Psychedelic Stocks Jump as High as 40% After Trump Supports Using Drugs Like LSD for Mental Health
Compass Pathways PLC (CMPS) Q1 2026 Earnings Call Transcript
FDA Greenlights First Ibogaine Derivative Trial and Fast‑tracks Three Psychedelics
MDMA-Assisted Therapy for Depression: A Promising but Early First Step
Psychedelic-Assisted Therapies Get a Boost, but Systems Struggle to Play Catch-Up
Why Trump Reversed Course to Fast-Track Psychedelic Drugs for Mental Healthcare
What Trump’s Psychedelics Executive Order Means for Basic Neuroscience
Psychedelics Space at a ‘Tipping Point’ as Compass, Definium Gear Up To File for Approval
Trump's Executive Order Fast‑Tracks Psychedelic Therapy Review, Boosting Compass Pathways
What Psychedelic Clinical Trials Could Teach Psychiatry
STAT+: FDA to Speed up Review of Three Psychedelics as Mental Health Treatments
Policy Watch: FDA Moves to Implement Trump Order on Psychedelic Drugs
Biogen Stops Part of an MS Trial; Merck Reports More Enflonsia Data
Who’s Winning Pharma’s Innovation Race? The Rankings Are Out.
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
Neuronetics Inc (STIM) Q1 2026 Earnings Call Transcript
FDA Moves to Speed Review Support for Psychedelic-Related Treatments
FDA Grants Quick Review Psychedelic Drugs, First Approvals Could Come As Soon As Summer
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine — Episode 248